Latest news with #Leerink
Yahoo
3 days ago
- Business
- Yahoo
Nuvalent price target raised to $140 from $125 at Leerink
Leerink raised the firm's price target on Nuvalent (NUVL) to $140 from $125 and keeps an Outperform rating on the shares. Nuvalent's zidesamtinib has demonstrated a best in class profile in the competitive ROS1 landscape, driven by 'unprecedented' durability and tolerability-attributes that have limited the commercial success of other ROS1 agents, the analyst tells investors in a research note. Leerink believes the drug has the potential to be a blockbuster in ROS1+ tumors across all lines of therapy. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on NUVL: Disclaimer & DisclosureReport an Issue Nuvalent price target raised to $130 from $110 at H.C. Wainwright Nuvalent's Zidesamib: Promising Best-in-Class ROS1 TKI with Strong Efficacy and Safety Profile Nuvalent Announces Positive Data for Zidesamtinib Trial Nuvalent Announces New Director and Annual Meeting Results Nuvalent's Zidesamtinib: Promising Efficacy and Safety Drive Buy Rating Sign in to access your portfolio
CNBC
4 days ago
- Business
- CNBC
Abbott jumps on RFK Jr. health push — plus, reviews of ELi Lilly's obesity drug data
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Markets: Stocks were rallying for the second day in a row as geopolitical tensions in the Middle East eased and oil prices plummeted. The S & P 500 rose more than 1% on Tuesday and was around session highs in late afternoon trading. Technology and financials were the two big sector winners of the day, with chip stocks surging and banks picking up steam ahead of a few highly anticipated regulatory events later this week, including the release of the Federal Reserve's annual stress tests results Friday. Obesity trial: Eli Lilly 's experimental weight-loss drug, designed to help patients preserve muscle mass, did not wow Wall Street. That was our takeaway from the analyst notes we read Tuesday, a day after Lilly presented mid-stage trial data on the drug, known as bimagrumab, at the American Diabetes Association's annual conference. As GLP-1 obesity drugs like Lilly's Zepbound and Novo Nordisk 's Wegovy have boomed in popularity, some observers have expressed concern about the amount of muscle mass that patients lose in addition to fat. The current ratio is usually around 70% fat and 30% muscle, "a significant burden for patients," according to Bernstein analysts. On this question, the bimagrumab data released Monday was generally viewed positively by the Street, with Leerink Partners saying it showed "compelling efficacy." Patients who took the highest dose of bimagrumab alongside the obesity drug semaglutide lost more fat than those who just took semaglutide – about 93% fat mass compared with 71.5%. Semaglutide is the active ingredient in Wegovy. Tirzepatide is the active ingredient in Lilly's Zepbound. However, Leerink and other Wall Street firms expressed some reservations about the tolerability and safety data, and what that means for its commercial prospects down the road. For that reason, Leerink and Jefferies analysts both said their financial models for Lilly continue to not include any sales contribution from bimagrumab. While Wolfe Research maintained its outperform buy rating on Lilly stock, the firm said "the safety and discontinuation rates keep us on the sidelines for now." More data is needed for both doctors and investors alike "to get a better sense of the commercial opportunity for this class of muscle preservation drugs," Wolfe Research wrote. The general sense is that bimagrumab wouldn't be broadly prescribed, but most likely used in more targeted populations where loss of muscle is a more pressing concern. In a note to clients on Tuesday, Bernstein said that could include elderly patients, as well as perhaps some patients who need to shed fewer overall pounds and simply "rebalance body composition." "Regardless, there's still much to play out," the analysts wrote, echoing Wolfe in saying that data from Lilly's ongoing trials for the drug will be necessary. For us, we agree with the Street on bimagrumab — and are much more focused on the development of Lilly's daily obesity pill orforglipron. Late-stage trial data for orforglipron is expected out in the third quarter. Wearables: Health & Human Services Secretary Robert F. Kennedy Jr. said Tuesday that his department plans to encourage the use of wearable health devices. "My vision is every American is wearing a wearable within four years," RFK Jr. said at a House Energy and Commerce Committee meeting . His comments sent shares of Abbott Laboratories and other continuous glucose monitor (CGM) device makers higher. We'll have to see the full details when the campaign comes out, but Abbott is well-positioned to benefit from the increased adoption of these devices. Not only does it have the best-selling CGM for diabetes patients in the Free Style Libre, but it also has a CGM available without a prescription in Lingo . Up next: FedEx reports earnings after Tuesday's close. General Mills reports before Wednesday's opening bell. On the economy, there is a slew of housing-related data out on Wednesday, including mortgage applications, new home sales, and building permits. (See here for a full list of the stocks in Jim Cramer's Charitable Trust.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED.
&w=3840&q=100)
Business Standard
09-06-2025
- Business
- Business Standard
Merck's potential cholesterol pill succeeds in late-stage studies
Merck's oral cholesterol pill succeeded in two late-stage studies, marking a win for the drugmaker as it focuses on the development of growth drivers beyond its cancer drugs and vaccines. The company is searching for its next blockbuster candidate as its major revenue driver, Keytruda, is expected to lose patent protection by the end of the decade. Merck's non-statin cholesterol drug, enlicitide decanoate, is being tested for the treatment of hyperlipidemia, a condition that causes elevated buildup of fat in the blood vessels and can lead to heart attacks and strokes. Enlicitide works by blocking PCSK9, a protein that plays a crucial role in regulating cholesterol levels, while statins block an enzyme the liver uses to make cholesterol. BMO Capital Markets analyst Evan Seigerman said Merck's drug could potentially provide a "multi-billion dollar opportunity" that expands the PCSK9 market beyond current injectable therapies. The drug showed meaningful reductions in LDL-C cholesterol, commonly referred to as "bad cholesterol", when compared to placebo and other oral non-statin therapies, Merck said. However, Leerink analysts have noted that Astrazeneca's AZD0780 is a "credible threat" as it has shown a 50.7% reduction in LDL-C levels during a trial. Merck has not given the details on LDL-C reduction for enlicitide. The drug was tested in patients who have a history of, or are at risk for a type of heart disease, and were treated with a statin. Shares of Merck were up 2% in premarket trading.
Business Insider
02-06-2025
- Business
- Business Insider
Arvinas downgraded to Market Perform from Outperform at Leerink
Leerink analyst Andrew Berens downgraded Arvinas (ARVN) to Market Perform from Outperform with a price target of $9, down from $10, after the company presented full results from the Phase 3 VERITAC-2 trial evaluating vepdegestrant in second-line HR+/HER2- metastatic breast cancer patients. The firm says that while the full presentation demonstrates the drug is active in patients with ESR1 mutations and likely approvable, it is not convinced vepdeg is best-in-class. Further, a number of key uncertainties in the rapidly evolving treatment paradigm for ESR1m breast cancer landscape have emerged, the analyst tells investors in a research note. Leerink 'gradually tempered the ESR1m rate in second-line from 30% to 15% to reflect potential impact from the SERENA-6 data, as well as ongoing first-line oral SERD trials, lowering its assumed worldwide peak vepdeg sales to $416M from $576M.
Business Insider
31-05-2025
- Business
- Business Insider
Regeneron price target lowered to $645 from $686 at Leerink
Leerink lowered the firm's price target on Regeneron (REGN) to $645 from $686 and keeps an Outperform rating on the shares. In the wake of itepekimab's failure in one of two Phase 3 COPD trials, the firm is removing the drug from its model and lowering its price target on the shares, the analyst tells investors in a research note. The firm noted that its investment thesis is that Regeneron shares can outperform from current levels because it expects growth to accelerate after a big Eylea sales/earnings stepdown in 2025; pipeline newsflow is likely to improve after several months of disappointing press releases, and; shares are trading near historical low multiple levels. The company should return to growth in 2026 and accelerate in 2027, the analyst adds. Confident Investing Starts Here:
